LabPMM Assay Guidelines Patient with suspected or confirmed AML diagnosis FLT3 or LeukoStrat® CDx FLT3 Mutation Assay NPM1 MyAML is a targeted gene panel that analyzes the coding and non-coding exons of nearly 200 genes, as well as the breakpoint hotspots within 36 genes. MyAML combines long read chemistry and deep sequencing with an optimized and validated custom bioinformatics pipeline, MyInformatics™, to specifically examine genomic variants in AML patients. Follow-up with MRD assays unique for biomarkers identified in each patient, such as FLT3 ITD MRD, NPM1 MRD and Consider testing with or as an entry point into clinical trials or to optimize treatment Our FLT3 ITD and NPM1 MRD tests are amplicon-based NGS assays, with a limit of detection of 5x10-5 8 Patient with suspected or confirmed hematological malignancy B- and T-cell clonality testing according to disorder Consider testing with or as an entry point into clinical trials For blood cancers other than AML, consider MyHEME. The MyHEME NGS panel identifies clinically actionable, pathogenic, and potentially pathogenic mutations in more than 700 genes associated with hematologic malignancies. Follow-up with MRD assays unique for biomarkers identified in each patient, such as IGH, IGK, TRG, TRB and The MyMRD is a NGS-based panel that assesses variants in hotspots from 23 genes that commonly drive myeloid malignancies, including AML, MPN and MDS. It can detect SNV, indels, and translocations to the genomic basepair, offering unparalleled precision and detection of low level mutations in patients. The MyMRD assay detects at least one driver mutation in 90%-95% of all AMLs. LabPMM Services Catalog 2019 | 9